Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Rayko Evstatiev"'
Autor:
Adrian Frick, Adam Cervenka, Andrea Beer, Maximilian Baumgartner, Rayko Evstatiev, Anita Krnjic, Christoph Gasche, Gunther Deim, Christina Gmainer, Helga Schachner, Michaela Lang, Tina Austerlitz, Vineeta Khare
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Scientific Reports
Scientific Reports
Inflammatory bowel disease is a group of conditions with rising incidence caused by genetic and environmental factors including diet. The chelator ethylenediaminetetraacetate (EDTA) is widely used by the food and pharmaceutical industry among numerou
Autor:
Anita Krnjic, Rayko Evstatiev, Kristine Jimenez, Maximilian Baumgartner, Christina Gmainer, Adrian Frick, Christoph Gasche, Michaela Lang, Mario Asboth, Vineeta Khare
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)
Scientific Reports
Scientific Reports
Disruption of mucosal structure and barrier function contribute to the pathogenesis of inflammatory bowel disease (IBD). Efficacy of therapy in IBD is based on endoscopic mucosal healing, which occurs by a dynamic interplay of epithelial cell regener
Autor:
Thierry Claudel, Alastair J.M. Watson, Michaela Lang, Jonathan M. Williams, Vineeta Khare, Rayko Evstatiev, Felix Harpain, Nicolas Granofszky, D. Mark Pritchard, Christoph Gasche, Kyle Dammann
Publikováno v:
Biochimica et Biophysica Acta
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research
P21-activated kinases (PAKs) are multifunctional effectors of Rho GTPases with both kinase and scaffolding activity. Here, we investigated the effects of inflammation on PAK1 signaling and its role in colitis-driven carcinogenesis. PAK1 and p-PAK1 (T
Autor:
Michaela Lang, Šárka Pospíšilová, Christoph Gasche, Melanie Borgmann, Boris Tichy, Maren Pflueger, Vineeta Khare, Harald Hundsberger, Alex Lyakhovich, Rayko Evstatiev, Gloria Luciani, Christoph Campregher, Kyle Dammann
Publikováno v:
Biochemical Pharmacology
Graphical abstract (a) PAK1 orchestrates mesalamine activity, (b) mesalamine inhibits PAK1; increases membranous E-cadherin and β-catenin; modulates cell adhesion
Mesalamine (5-ASA) is widely used for the treatment of ulcerative colitis, a remi
Mesalamine (5-ASA) is widely used for the treatment of ulcerative colitis, a remi
Autor:
Michaela, Lang, David, Berry, Katharina, Passecker, Ildiko, Mesteri, Sabin, Bhuju, Florian, Ebner, Vitaly, Sedlyarov, Rayko, Evstatiev, Kyle, Dammann, Alexander, Loy, Orest, Kuzyk, Pavel, Kovarik, Vineeta, Khare, Martin, Beibel, Guglielmo, Roma, Nicole, Meisner-Kober, Christoph, Gasche
Publikováno v:
Cancer research. 77(9)
HuR is an RNA-binding protein implicated in immune homeostasis and various cancers, including colorectal cancer. HuR binding to AU-rich elements within the 3′ untranslated region of mRNAs encoding oncogenes, growth factors, and various cytokines le
Autor:
Michaela Lang, Rayko Evstatiev, Azra Kurtovic, Christoph Gasche, Ildiko Mesteri, Kyle Dammann, Vineeta Khare, Felix Harpain
Publikováno v:
Cancer prevention research (Philadelphia, Pa.). 8(11)
p21-activated kinase 1 (PAK1) is a serine/threonine kinase that is overexpressed in colorectal cancer. PAK1 is a target of mesalamine [5-aminosylicylic acid (5-ASA)], a common drug for the treatment of ulcerative colitis with prospective chemoprevent